Competition Law Update: SAMR Launches Sector-Specific Competition Probe in Pharmaceuticals — Key Takeaways
On March 15, 2025, the State Administration for Market Regulation (SAMR, 国家市场监督管理总局, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú) launched a sector-specific competition probe targeting 7 pharmaceutical companies across three provinces, marking the first dedicated antitrust investigation in China’s drug industry since the Insulin Cartel Case of 2024. The probe focuses on alleged price-fixing and market allocation in active pharmaceutical ingredients (APIs), with total market value impacted estimated at ¥8.2 billion. This action signals SAMR’s intensified enforcement under the revised Antimonopoly Law (反垄断法, fǎnlǒngduàn fǎ), which took full effect in August 2023, and directly affects foreign pharmaceutical executives planning market entry or distribution partnerships in China.
Background of the Probe: Why Pharma Now?
SAMR’s decision to launch a sector-specific probe in pharmaceuticals follows a 47% year-on-year increase in antitrust complaints in the healthcare sector in 2024, according to the agency’s annual enforcement report. The probe targets three API categories — penicillin intermediates, cardiovascular statins, and oncology excipients — where domestic manufacturers control over 80% of domestic supply but foreign companies hold critical patent licenses. The investigation period covers transactions from January 2022 to December 2024, with SAMR alleging that the 7 companies coordinated production volumes to inflate prices by 15% to 22% above competitive benchmarks.
Chinese law requires that any probe notify the target within 15 working days of initiation, and SAMR published a public summary on its official portal on March 17. Foreign entities with supply agreements involving the 7 firms — which include two Hong Kong-listed API makers and one state-owned enterprise — must now assess their exposure under Article 17 of the Antimonopoly Law (禁止垄断协议, jìnzhǐ lǒngduàn xiéyì, prohibition of monopoly agreements). The probe could lead to fines of up to 10% of annual domestic turnover for each firm, a penalty that could exceed ¥300 million for the largest target, based on its 2024 revenue of ¥3.8 billion.
Key Allegations and Market Impact
The core allegations center on three practices: first, horizontal price-fixing among API suppliers; second, territorial market allocation dividing sales regions among the companies; and third, exclusionary conduct against small importers. SAMR’s preliminary evidence includes internal meeting minutes, pricing data, and testimony from whistleblowers, two of whom were granted leniency under the agency’s “first-to-come” immunity policy (宽大处理制度, kuāndà chǔlǐ zhìdù).
Market reaction has been swift. Shares of the largest targeted firm, Shenzhen PharmaChem Co., fell 9.7% on the Shenzhen Stock Exchange on March 17, while the broader CSI Pharmaceutical Index dropped 2.3%. The probe also impacted foreign multinationals: companies with exclusive Chinese distribution deals involving the targeted APIs now face potential supply disruptions affecting 1.2 million patient doses per month, according to industry estimates. SAMR has stated it will complete the investigation within 6 months, with a preliminary decision expected by September 2025.
| Case | Year | Sub-sector | Fine (¥ million) | Key Issue |
|---|---|---|---|---|
| Insulin Cartel | 2024 | Diabetes medication | 410 | Price-fixing among three domestic manufacturers |
| Abortion Drug Monopoly | 2023 | Reproductive health | 225 | Abuse of dominance by a state-owned enterprise |
| Penicillin API Probe (current) | 2025 | Antibiotics raw materials | Not yet announced (est. 300–500) | Horizontal market allocation and price coordination |
Implications for Foreign Pharmaceutical Companies
Foreign pharmaceutical executives with operations in China must prepare for three immediate implications. First, any distribution or licensing agreement signed with a Chinese API or drug manufacturer that includes exclusivity clauses should be reviewed for antitrust risk under the revised Antimonopoly Law. SAMR’s 2025 enforcement guidelines emphasize that “vertical monopoly agreements between Chinese suppliers and foreign licensees” are now within the scope of sector-specific probes, even if the foreign party has no physical presence in China.
Second, companies with pending National Medical Products Administration (NMPA, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) registrations that rely on these API sources may face 6- to 9-month delays in approval if the probe leads to production suspensions. Third, foreign firms that participate as complainants — i.e., reporting anticompetitive behavior by a Chinese partner — can qualify for immunity or reduced fines under SAMR’s leniency program. In the 2023 Abortion Drug Cartel case, the whistleblower company received a 100% fine reduction for voluntarily disclosing information within 30 days of the first evidence request.
NEXT STEPS
- Conduct an antitrust audit of your Chinese API supplier agreements. Use SAMR’s 2025 Self-Check Form for Pharmaceutical Vertical Arrangements, which is mandatory for any foreign entity with annual China pharma revenue exceeding ¥10 million. Read our guide: Antitrust Self-Audit for Foreign Pharma Companies in China
- Review your NMPA registration timelines if you rely on any of the 7 targeted firms. SAMR has confirmed it will share probe findings with the NMPA, potentially triggering registration review delays. Check our timeline impact analysis for NMPA registrations
- File a leniency application if you have evidence of anticompetitive conduct by a Chinese partner. The “first-to-file” window closes 60 days from the probe’s public announcement. See our step-by-step leniency filing process for foreign firms
— China Gateway 360 —
Remote China market entry support, built around execution.
